Trial · NCT07895342
Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
NCT07895342, Not applicable, Not yet recruiting, Radboud University Medical Center
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma. Trials, record NCT07895342. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895342
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Overcoming Immunotherapy Resistance in Hepatocellular Carcinoma
- NCT number
- NCT07895342
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 16 participants, estimated
- Lead sponsor
- Radboud University Medical Center
- Conditions
- Hepatocellular Carcinoma Non-Resectable
- Interventions
- External beam radiotherapy, transarterial radioembolization
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The 6-month disease control rate | The 6-month disease control rate will be calculated from randomization to the date of the CT scan of chest and abdomen planned at 6 months post-randomization (+/- 7 days). | The 6-month disease control rate is defined by stable disease for at least 6 months, partial responses, and complete responses of non-targeted lesions, in both cohort A and B, according to RECIST version 1.1. |
| Secondary | Objective response rate | Complete duration of study up to 24 weeks | The objective response rate is defined as the percentage of patients who experience a partial or complete response of non-targeted lesions, according to RECIST version 1.1. |
| Secondary | Progression-free survival | From date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 60 months | The progression-free survival is defined as the time interval from randomization to the first event of disease progression, according to RECIST version 1.1, or death, whichever comes first. Kaplan-Meier curves will be shown. This study is not designed to show differences between cohort A and B. |
| Secondary | Overall survival | From the date of randomization to the date of death from any cause assessed up to 60 months | Overall survival is calculated from the date of randomization to the date of death due to any cause. For patients alive at trial closure, date of last follow-up. Kaplan-Meier curves will be shown. This study is not designed to show differences between cohort A and B. |
| Secondary | Therapy-related toxicity | Up to three months after the last radiotherapy fraction (cohort A) or radio-embolization (cohort B). | This is defined as the number of patients with any grade ≥ 3 therapy-related toxicity according to the CTCAE version 5.0. |
| Secondary | Feasibility of treatment | Through study completion, an average of 6 months | Study feasibility of post-immunotherapy treatment is defined as: 1) the proportion of patients that complete all radiotherapy fractions (cohort A) and radioembolization (cohort B); 2) the proportion of patients that complete all study-related imaging, blood withdrawal and biopsies (cohort A and B). |
| Secondary | Health-related Quality of life | At baseline, 72-120h post treatmen, 3 months post treatment and 6 months post treatment (EOT) | Health-Related Quality of Life (HRQoL) will be scored and reported according to the EORTC scoring manual (19). Descriptive statistics will be reported per treatment arm. Quality of Life Symptom Scale: Scores range from 1 to 4, where 1 = not at all bothered by the symptom and 4 = very much bothered by the symptom. Higher scores indicate greater symptom burden and therefore a worse outcome. |
| Other | Translational immune landscape studies | Through study completion (up to approximately 18 months after the inclusion of the last patient) | In-depth translational immune landscape studies will be performed. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895342
GET https://conductscience.org/api/trials/v1/NCT07895342/registered